S-propargyl-cysteine, a novel water-soluble modulator of endogenous hydrogen sulfide, promotes angiogenesis through activation of signal transducer and activator of transcription 3

Antioxidants and Redox Signaling

Volumn 20, Issue 15, 2014, Pages 2303-2316

  Kan, Juntao ^a   Guo, Wei ^a   Huang, Chengrong ^a   Bao, Guangzhi ^a   Zhu, Yichun ^a   Zhu, Yi Zhun ^a,b  

^a FUDAN UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN SULFIDE; MATRIGEL; S PROPARGYLCYSTEINE; STAT3 PROTEIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENIC FACTOR; CYSTEINE; PROTEIN BINDING; S-PROPARGYLCYSTEINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY LIGATION; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORONARY ARTERY; CRYSTALLIZATION; FEMORAL ARTERY; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEG ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; RNA INTERFERENCE; TRANSCRIPTION INITIATION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR RING; ACTIVE TRANSPORT; ANALOGS AND DERIVATIVES; ANIMAL; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; MALE; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT;

ACTIVE TRANSPORT, CELL NUCLEUS; ANGIOGENESIS INDUCING AGENTS; ANIMALS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CYSTEINE; DISEASE MODELS, ANIMAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROGEN SULFIDE; MALE; MICE; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN BINDING; PROTEIN TRANSPORT; RATS; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84899631426     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5449     Document Type: Article

References (39)

1. Abe K and Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 16: 1066-1071, 1996.
2. Bartoli M, Gu XL, Tsai NT, Venema RC, Brooks SE, Marrero MB, and Caldwell RB. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J Biol Chem 275: 33189-33192, 2000.
3. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao YX, Pestell RG, Albanese C, and Darnell JE. Stat3 as an oncogene. Cell 98: 295-303, 1999.
4. Cai WJ, Wang MJ, Moore PK, Jin HM, Yao T, and Zhu YC. The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation. Cardiovasc Res 76: 29-40, 2007.
5. Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, Pattillo CB, Kevil CG, and Lefer DJ. Hydrogen Sulfide Mediates Cardioprotection Through Nrf2 Signaling. Circ Res 105: 365-U105, 2009.
6. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438: 932-936, 2005.
7. Chalothorn D, Clayton JA, Zhang H, Pomp D, and Faber JE. Collateral density, remodeling, and VEGF-A expression differ widely between mouse strains. Physiol Genomics 30: 179-191, 2007.
8. Ferrara N, Gerber HP, and LeCouter J. The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
9. Frontini MJ, Nong Z, Gros R, Drangova M, O'Neil C, Rahman MN, Akawi O, Yin H, Ellis CG, and Pickering JG. Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells. Nat Biotechnol 29: 421-427, 2011.
10. Givvimani S, Tyagi N, Sen U, Mishra PK, Qipshidze N, Munjal C, Vacek JC, Abe OA, and Tyagi SC. MMP-2/TIMP- 2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem 116: 63-72, 2010.
11. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, and Gallick GE. HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24: 3110-3120, 2005.
12. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, Hillmer A, Schmiedl A, Ding ZP, Podewski E, Poli V, Schneider MD, Schulz R, Park JK, Wollert KC, and Drexler H. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 95: 187-195, 2004.
13. Holmgren A. Thioredoxin structure and mechanism: conformational changes on oxidation of the active-site sulfhydryls to a disulfide. Structure 3: 239-243, 1995.
14. Huang C, Kan J, Liu X, Ma F, Tran BH, Zou Y, Wang S, and Zhu YZ. Cardioprotective effects of a novel hydrogen sulfide agent-controlled release formulation of s-propargyl-cysteine on heart failure rats and molecular mechanisms. PLoS One 8: e69205, 2013.
15. Levy DE and Darnell JE. STATs: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662, 2002.
16. Limbourg A, Korff T, Napp LC, Schaper W, Drexler H, and Limbourg FP. Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. Nat Protoc 4: 1737-1748, 2009.
17. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, and Isner JM. Gene therapy for myocardial angiogenesis - Initial clinical results with direct myocardial injection of phVEGF(165) as sole therapy for myocardial ischemia. Circulation 98: 2800-2804, 1998.
18. Mustafa AK, Gadalla MM, Sen N, Kim S, Mu WT, Gazi SK, Barrow RK, Yang GD, Wang R, and Snyder SH. H2S Signals Through Protein S-Sulfhydration. Sci Signal 2, 2009.
19. Niu GL, Wright KL, Huang M, Song LX, Haura E, Turkson J, Zhang SM, Wang TH, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, and Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002.
20. Olsson AK, Dimberg A, Kreuger J, and Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371, 2006.
21. Organization WH. The 10 Leading Causes of Death in the World, 2000 and 2011. Geneva: World Health Organization, 2013.
22. Osugi T, Oshima Y, Fujio Y, Funamoto M, Yamashita A, Negoro S, Kunisada K, Izumi M, Nakaoka Y, Hirota H, Okabe M, Yamauchi-Takihara K, Kawase I, and Kishimoto T. Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J Biol Chem 277: 6676-6681, 2002.
23. Pan LL, Liu XH, Gong QH, Yang HB, and Zhu YZ. Role of cystathionine γ-lyase/hydrogen sulfide pathway in cardiovascular disease: a novel therapeutic strategy? Antioxid Redox Signal 17: 106-118, 2012.
24. Papapetropoulos A, Pyriochou A, Altaany Z, Yang GD, Marazioti A, Zhou ZM, Jeschke MG, Branski LK, Herndon DN, Wang R, and Szabo C. Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci U S A 106: 21972-21977, 2009.
25. Predmore BL, Lefer DJ, and Gojon G. Hydrogen sulfide in biochemistry and medicine. Antioxid Redox Signal 17: 119-140, 2012.
26. Schumacher B, Pecher P, von Specht BU, and Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors - First clinical results of a new treatment of coronary heart disease. Circulation 97: 645-650, 1998.
27. Srivastava K, Kundumani-Sridharan V, Zhang B, Bajpai AK, and Rao GN. 15 (S)-Hydroxyeicosatetraenoic Acid-Induced Angiogenesis Requires STAT3-Dependent Expression of VEGF. Cancer Res 67: 4328-4336, 2007.
28. Tao BB, Liu SY, Zhang CC, Fu W, Cai WJ, Wang Y, Shen Q, Wang MJ, Chen Y, Zhu YZ, and Zhu YC. VEGFR2 functions as an H2S-targeting receptor protein kinase with its novel Cys1045-Cys1024 disulfide bond serving as a specific molecular switch for hydrogen sulfide actions in vascular endothelial cells. Antioxid Redox Signal 19: 448-464, 2012.
29. van der Laan AM, Piek JJ, and van Royen N. Targeting angiogenesis to restore the microcirculation after reperfused MI. Nat Rev Cardiol 6: 515-523, 2009.
30. Wang MJ, Cai WJ, Li N, Ding YJ, Chen Y, and Zhu YC. The Hydrogen Sulfide Donor NaHS Promotes Angiogenesis in a Rat Model of Hind Limb Ischemia. Antioxid Redox Signal 12: 1065-1077, 2010.
31. Wang Q, Liu HR, Mu Q, Rose P, and Zhu YZ. S-propargylcysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway. J Cardiovasc Pharmacol 54: 139-146, 2009.
32. Wang Q, Wang XL, Liu HR, Rose P, and Zhu YZ. Protective effects of cysteine analogues on acute myocardial ischemia: novel modulators of endogenous H(2)S production. Antioxid Redox Signal 12: 1155-1165, 2010.
33. Xu Q, Briggs J, Park S, Niu GL, Kortylewski M, Zhang SM, Gritsko T, Turkson J, Kay H, Semenza GL, Cheng JQ, Jove R, and Yu H. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24: 5552-5560, 2005.
34. Yahata Y, Shirakata Y, Tokumaru S, Yamasaki K, Sayama K, Hanakawa Y, Detmar M, and Hashimoto K. Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J Biol Chem 278: 40026-40031, 2003.
35. Yellon DM and Hausenloy DJ. Mechanisms of disease: myocardial reperfusion injury. N Engl JMed 357: 1121-1135, 2007.
36. Yla-Herttuala S and Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 9: 694-701, 2003.
37. Zhao WM, Zhang J, Lu YJ, and Wang R. The vasorelaxant effect of H2S as a novel endogenous gaseous K-ATP channel opener. EMBO J 20: 6008-6016, 2001.
38. Zhong Z, Wen ZL, and Darnell JE. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth-factor and interleukin-6. Science 264: 95-98, 1994.
39. Zhu YZ, Wang ZJ, Ho PY, Loke YY, Zhu YC, Huang SH, Tan CS, Whiteman M, Lu J, and Moore PK. Hydrogen sulfide and its possible roles in myocardial ischemia in experimental rats. J Appl Physiol 102: 261-268, 2007.